Moderna, Inc. (MRNA)
After hours:
| Previous close | 182.35 |
| Open | 180.99 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 173.59 - 183.68 |
| 52-week range | 115.03 - 321.30 |
| Volume | |
| Avg. volume | 4,758,662 |
| Market cap | 71.331B |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
EQS Newswire / 01/11/2022 / 04:21 EST/EDTMinistry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222 CAMBRIDGE, MA / ACCESSWIRE / November 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a pa
- EQS Group
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
EQS Newswire / 12/09/2022 / 23:52 EST/EDTMinistry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214CAMBRIDGE, MA / ACCESSWIRE / September 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a p
- EQS Group
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
EQS Newswire / 08/09/2022 / 23:42 EST/EDTModerna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D DayInterim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefitInterim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefitModern
